enGene
My Lan TRAN is an Associate Scientist at enGene since April 2023, focusing on CMC. Previously, My Lan TRAN completed a PhD project at Laboratoire SPCMIB from October 2019 to December 2022, working on (hetero)multivalent dendrimers for polypharmacological approaches against Gaucher disease, which involved total synthesis of bioactive compound analogs, dendrimer-based pharmacological chaperones, and various biological evaluations. Academic experience includes a Master 2 research internship at SPCMIB in 2019 on new multivalent structures, and a Master 1 research internship at CNRS focused on chiral ferrocenyl ligands in 2018. My Lan TRAN holds a Master 2 in Health Chemistry from Université Paul Sabatier Toulouse III and a Master 1 in General Chemistry from Pierre and Marie Curie University, alongside a Licence in Chemistry from the same institution and preliminary education in science and technology.
enGene
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications